Gene therapy and targeted toxins for glioma
MG Castro, M Candolfi, KM Kroeger… - Current gene …, 2011 - ingentaconnect.com
The most common primary brain tumor in adults is glioblastoma. These tumors are highly
invasive and aggressive with a mean survival time of 15-18 months from diagnosis to death …
invasive and aggressive with a mean survival time of 15-18 months from diagnosis to death …
Tissue-specific promoters for cancer gene therapy
K Saukkonen, A Hemminki - Expert opinion on biological therapy, 2004 - Taylor & Francis
Adenoviral cancer gene therapy approaches have resulted in promising recent results.
Following only a decade of intense development, some of the crucial obstacles are now …
Following only a decade of intense development, some of the crucial obstacles are now …
Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression
OD Perez, CR Logg, K Hiraoka, O Diago, R Burnett… - Molecular Therapy, 2012 - cell.com
Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses
as anticancer agents, being selective both for dividing cells and for cells that have defects in …
as anticancer agents, being selective both for dividing cells and for cells that have defects in …
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma
CK Tai, WJ Wang, TC Chen, N Kasahara - Molecular Therapy, 2005 - cell.com
Achieving therapeutically efficacious levels of gene transfer in tumors has been a major
obstacle for cancer gene therapy using replication-defective virus vectors. Recently …
obstacle for cancer gene therapy using replication-defective virus vectors. Recently …
Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity
K Hiraoka, A Inagaki, Y Kato, TT Huang… - Neuro …, 2017 - academic.oup.com
Background. Prodrug-activator gene therapy with Toca 511, a tumor-selective retroviral
replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent …
replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent …
Recent progress in the research of suicide gene therapy for malignant glioma
Malignant glioma, which is characterized by diffuse infiltration into the normal brain
parenchyma, is the most aggressive primary brain tumor with dismal prognosis. Over the …
parenchyma, is the most aggressive primary brain tumor with dismal prognosis. Over the …
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
E Chen, AL Ling, DA Reardon, EA Chiocca - Neuro-oncology, 2024 - academic.oup.com
Glioblastoma (GBM)'s median overall survival is almost 21 months. Six phase 3
immunotherapy clinical trials have recently been published, yet 5/6 did not meet approval by …
immunotherapy clinical trials have recently been published, yet 5/6 did not meet approval by …
Optimal delivery of RNA interference by viral vectors for cancer therapy
In recent years, there has been a surge in the innovative modification and application of the
viral vector-based gene therapy field. Significant and consistent improvements in the …
viral vector-based gene therapy field. Significant and consistent improvements in the …
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model
TT Huang, S Parab, R Burnett, O Diago… - Human gene …, 2015 - liebertpub.com
Abstract Toca 511 (vocimagene amiretrorepvec), a nonlytic, amphotropic retroviral
replicating vector (RRV), encodes and delivers a functionally optimized yeast cytosine …
replicating vector (RRV), encodes and delivers a functionally optimized yeast cytosine …
Therapeutic Efficacy of Replication-Competent Retrovirus Vector–Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model
K Hiraoka, T Kimura, CR Logg, CK Tai, K Haga… - Cancer research, 2007 - AACR
Replication-competent retrovirus (RCR) vectors are intrinsically incapable of infecting
quiescent cells and have been shown to achieve highly efficient and tumor-restricted …
quiescent cells and have been shown to achieve highly efficient and tumor-restricted …